Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:24 PM
Ignite Modification Date:
2025-12-24 @ 3:24 PM
NCT ID:
NCT03721692
Eligibility Criteria:
Inclusion Criteria:
1. Patients who suffered an ischemic stroke within 14 days prior to enrollment
2. With a baseline NIHSS score 0-15, mRS score 2-4
3. With at least one cerebral and carotid artery stenosis over 50%
4. With at least one coronary artery stenosis over 50% or previous myocardial ischemic events history(tertiary hospital doctors judge angina, myocardial infarction, and coronary revascularization treatment)
5. Age from 18 to 80
6. Informed consent obtained
Exclusion Criteria:
1. Thrombolytic therapy within 24 h prior to enrollment
2. Progressive neurological signs within 24 h prior to enrollment
3. Arterial stenosis due to unequivocal cardiac source of embolism, arterial dissection, vasculitic disease, cerebral venous thrombosis, Moyamoya disease
4. Arterial stenosis due to benign angiopathy of central nervous system, post-partum angiopathy, suspected vasospastic process, suspected recanalized embolus, neurosyphilis, any other intracranial infection
5. Rheumatic mitral disease with or without aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, patent foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis
6. Uncontrolled severe hypertension, defined by sitting systolic blood pressure(SBP) \> 180 mm Hg and/or sitting diastolic blood pressure(DBP) \> 110 mm Hg after medication
7. Contraindication for remote ischemic conditioning, including severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs
8. Subclavian arterial stenosis 50% or subclavian steal syndrome
9. Severe hemostatic disorder or severe coagulation dysfunction, platelets \< 100 ×10\^9/L
10. Aspartate aminotransferase(AST) and/or Alanine aminotransferanse(ALT) \> 3× the upper limit of the reference range; creatinine clearance \< 0.6 mL/s and/or serum creatinine \> 265 mmol/L (\>3.0 mg/dL)
11. Unwilling to comply with the treatment or follow-up assessments
12. Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, or epidural) within 90 days prior to enrollment
13. Intracranial neoplasm, cerebral aneurysm, or arteriovenous malformation
14. Retinal hemorrhage or visceral bleeding within 30 days prior to enrollment
15. Major surgery, including cardiac and open femoral, aortic, or carotid surgery, within 30 days prior to enrollment or intent to undergo within 12 months after enrollment
16. Life expectancy \< 3 years
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT03721692
Study Brief:
Protocol Section:
NCT03721692